Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Francesco Costacurta"'
Autor:
Laura Krismer, Helge Schöppe, Stefanie Rauch, David Bante, Bernhard Sprenger, Andreas Naschberger, Francesco Costacurta, Anna Fürst, Anna Sauerwein, Bernhard Rupp, Teresa Kaserer, Dorothee von Laer, Emmanuel Heilmann
Publikováno v:
npj Viruses, Vol 2, Iss 1, Pp 1-20 (2024)
Abstract The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an epidemic, zoonotically emerging pathogen initially reported in Saudi Arabia in 2012. MERS-CoV has the potential to mutate or recombine with other coronaviruses, thus acquiring
Externí odkaz:
https://doaj.org/article/1322a7caaeab4ab2b156087e0d939fa6
Autor:
Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe, Ju-Yi Peng, Bernhard Sprenger, Xi He, Seyed Arad Moghadasi, Lisa Maria Egger, Jakob Fleischmann, Matteo Pavan, Davide Bassani, Silvia Menin, Stefanie Rauch, Laura Krismer, Anna Sauerwein, Anne Heberle, Toni Rabensteiner, Joses Ho, Reuben S Harris, Eduard Stefan, Rainer Schneider, Theresia Dunzendorfer-Matt, Andreas Naschberger, Dai Wang, Teresa Kaserer, Stefano Moro, Dorothee von Laer, Emmanuel Heilmann
Publikováno v:
PLoS Pathogens, Vol 20, Iss 9, p e1012522 (2024)
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2 main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available
Externí odkaz:
https://doaj.org/article/8a2d120a7782489fb1d69e04556b8418
Autor:
Emmanuel Heilmann, Francesco Costacurta, Stephan Geley, Seyad Arad Mogadashi, Andre Volland, Bernhard Rupp, Reuben Stewart Harris, Dorothee von Laer
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-12 (2022)
A vesicular stomatitis virus (VSV)-based assay enables high-throughput screening for small molecular protease inhibitors that can block viral proteases, like the Mpro/3CLpro/Nsp5 in SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/ca9da23218ea4e68b17aa315026f2d0f
Autor:
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, Andre Volland, Claudia Ascher, Alexander Kurt Hermann Weiss, David Bante, Reuben S. Harris, Stefano Moro, Bernhard Rupp, Luis Martinez-Sobrido, Dorothee von Laer
Publikováno v:
Science Translational Medicine. 15
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL pro that has been licensed for clinical use. To identify mutations that confer re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0448e7f05cc1a918bd239d187ffc59bb
https://doi.org/10.1126/scitranslmed.abq7360
https://doi.org/10.1126/scitranslmed.abq7360
Autor:
Emmanuel, Heilmann, Francesco, Costacurta, Seyed Arad, Moghadasi, Chengjin, Ye, Matteo, Pavan, Davide, Bassani, Andre, Volland, Claudia, Ascher, Alexander Kurt Hermann, Weiss, David, Bante, Reuben S, Harris, Stefano, Moro, Bernhard, Rupp, Luis, Martinez-Sobrido, Dorothee, von Laer
Publikováno v:
Science translational medicine.
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor against the SARS-CoV-2 protease 3CL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a3d9b4cee0dda553cbf0f1adff31464
https://pubmed.ncbi.nlm.nih.gov/36194133
https://pubmed.ncbi.nlm.nih.gov/36194133
Protease inhibitors are among the most powerful antiviral drugs. A first protease inhibitor against the SARS-CoV-2 protease 3CLpro, Paxlovid (nirmatrelvir / ritonavir), has recently been authorized by the U.S. FDA for emergency use (EUA 105 Pfizer Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b53353ad8ff2ae2f80938b678b4dcc1
https://doi.org/10.1101/2022.07.02.495455
https://doi.org/10.1101/2022.07.02.495455
